Abstract Number: 1072 • ACR Convergence 2022
Efficacy and Safety Assessment of a Rituximab Biosimilar in Patients with Granulomatosis with Polyangiitis (GPA)
Background/Purpose: A biosimilar is a medication that is highly similar to a biologic agent that is already approved by a regulatory organization. Considering the share…Abstract Number: 1080 • ACR Convergence 2022
Performance of Risk Prediction Models for Relapse and Severe Infection at the End of 18-month Rituximab Maintenance Therapy in ANCA-associated Vasculitides: Data from the MAINRITSAN Trials
Background/Purpose: Long-term follow-up analysis of the three MAINRITSAN trials confirmed the efficacy of rituximab (RTX) in preventing relapses in ANCA-associated vasculitis (AAV), especially RTX administration…Abstract Number: 1082 • ACR Convergence 2022
Outcomes of Methotrexate as an Initial Induction and Maintenance Regimen for Localized Granulomatosis with Polyangiitis: A Retrospective Review
Background/Purpose: While there is established data regarding the induction and maintenance treatment of systemic or organ threatening granulomatosis with polyangiitis (GPA), there is limited data…Abstract Number: 0431 • ACR Convergence 2021
Clinical Characteristics and Outcomes of ANCA-Associated and Non Immune-Mediated Hypertrophic Pachymeningitis: A Comparative Study
Background/Purpose: Hypertrophic pachymeningitis (HP) is an infrequent manifestation in autoimmune and non-autoimmune conditions. The differences in clinical characteristics and outcomes of ANCA-associated and non-immune-mediated HP…Abstract Number: 0436 • ACR Convergence 2021
Ocular and Orbital Manifestations of Granulomatosis with Polyangiitis: A Systematic Review of Published Cases
Background/Purpose: Granulomatosis with polyangiitis (GPA), formerly known as Wegener’s Granulomatosis, is a systemic autoimmune condition caused by granulomatous inflammation of small and medium arteries, arterioles…Abstract Number: 0525 • ACR Convergence 2021
STEAP3, FZD2 and EGFLAM Are Novel Genetic Risk Loci for Granulomatosis with Polyangitis: A Genome Wide Association Study from UK Biobank
Background/Purpose: Granulomatosis with Polyangitis (GPA) is a systemic ANCA associated small vessel vasculitis. Prior genetic studies demonstrated a strong association of HLA Class II region…Abstract Number: 0416 • ACR Convergence 2021
Pharmacological Response of Rituximab Based on Dose Intensity in Maintenance Therapy of ANCA-Associated Vasculitis
Background/Purpose: Rituximab (RTX) has demonstrated efficacy in maintenance therapy in ANCA-associated vasculitis. However, different dosing protocols have been used in clinical trials and there is…Abstract Number: 0421 • ACR Convergence 2021
Negative vs. Positive Antineutrophil Cytoplasmic Antibody Granulomatosis with Polyangiitis, a Case-control Study
Background/Purpose: Antineutrophil cytoplasmic antibody (ANCA) negative granulomatosis with polyangiitis (GPA) is a challenging diagnosis. There is paucity of literature regarding the clinical course of ANCA-negative…Abstract Number: 0060 • ACR Convergence 2020
ANCA-associated Vasculitis in Caucasian and Hispanics of the Inland Empire of Southern California
Background/Purpose: ANCA-associated vasculitis (AAV) is often studied in the Caucasian population with few studies looking at the disease in other races. Disease presentation and treatment…Abstract Number: 1032 • ACR Convergence 2020
Epidemiology and Geographic Evaluation of ANCA-associated Vasculitis (AAV) at a Rural Academic Health Center Utilizing an Electronic Health Record (EHR)
Background/Purpose: ANCA-associated vasculitis has a reported prevalence ranging from 3.2 to 9.1 cases per 100,000 individuals, but little is known of geographic variations. The aim of…Abstract Number: 1417 • ACR Convergence 2020
Risk of Relapse of ANCA-associated Vasculitis in Patients of 75 Years and Older: A Retrospective Study
Background/Purpose: ANCA-associated vasculitis (AAV) frequently occurs among older patients, with different clinical presentations than the younger. Little is known on the outcome of older patients…Abstract Number: 1418 • ACR Convergence 2020
Clinical Presentations and Follow-up Results of Granulomatosis with Polyangiitis: An Analysis of 8 Years Clinical Experience with 220 Patients from a National Referral Center
Background/Purpose: Granulomatosis with polyangiitis (GPA) is a rare and life-threatening autoimmune disease. Due to the extremely low prevalence of GPA, monitoring of clinical characteristics and…Abstract Number: 1420 • ACR Convergence 2020
Characterization of ANCA-Associated Vasculitis Among African American Patients
Background/Purpose: ANCA-associated vasculitis (AAV) comprises a group of disorders characterized by inflammation of small and medium-sized arteries. Prevalence and phenotype of these diseases appear to…Abstract Number: 1421 • ACR Convergence 2020
Clinical Features, Disease Activity and Prognosis of ANCA-Associated Vasculitis in US African Americans
Background/Purpose: ANCA-associated vasculitis (AAV), including Granulomatosis with Polyangiitis (GPA), Eosinophilic Granulomatosis with Polyangiitis (EGPA) and Microscopic Polyangiitis (MPA), affect mostly Caucasians of European descent. Clinical…Abstract Number: 1425 • ACR Convergence 2020
Reduced Risk of Cardiovascular Diseases Events with Renal Transplantation in Granulomatosis with Polyangiitis in the United States: Data from the US Renal Data System
Background/Purpose: Granulomatosis with polyangiitis (GPA) is a common cause of glomerulonephritis and leads to end-stage renal disease (ESRD) in approximately 25% of patients. Both GPA…